eBulletin Newsletter

NCCN Flash Updates: NCCN Guidelines and NCCN Templates Updated

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Ovarian Cancer, and the NCCN Drugs & Biologics Compendium (NCCN Compendium^®). These NCCN Guidelines^® are currently available as Version 3.2021. 

Link directly to the Updates section of the NCCN Guidelines: 
Ovarian Cancer

• Principles of Systemic Therapy, Acceptable Recurrence Therapies (OV-C 8 & 9 of 11)
  • Useful in certain circumstances
    • Option added for platinum-resistant and platinum-sensitive disease: Dostarlimab-gxly (for dMMR/MSI-H recurrent or advanced tumors, if disease progression and no satisfactory alternative treatment options).
    • Reference: Berton D, Banerjee S, Curigliano G, et al. Antitumor activity of dostarlimab in patients with mismatch repair–deficient (dMMR) tumors: a combined analysis of 2 cohorts in the GARNET study. Poster presented at American Society for Clinical Oncology (ASCO), Virtual Meeting, June 4–8, 2021. [Abstract ID: 2564].

Previous updates to the NCCN Guidelines for Ovarian Cancer can be found in the UPDATES section of the current version.




NCCN has published updates to the NCCN Guidelines and the NCCN Compendium^® for B-Cell Lymphomas. These NCCN Guidelines are currently available as Version 5.2021. 

Link to the NCCN Guidelines: 
B-Cell Lymphomas

• Marginal Zone Lymphomas (MZL-A 2 of 4)
  • Second-Line and Subsequent Therapy (for fit patients and elderly or infirm)
    • Zanubrutinib was added as a category 2A, preferred recommendation for relapsed/refractory disease after at least one prior anti-CD20-mAB-based regimen.
• Special Considerations for the use of zanubrutinib updated to be consistent with the prescribing information. (NHODG-E 8 of 8)

Previous updates to the NCCN Guidelines for B-Cell Lymphomas can be found in the UPDATES section of the current version.




NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates^®) for Breast Cancer to reflect the currently published NCCN Guidelines for Breast Cancer v8.2021.

• The following NEW NCCN Template® has been published:
  • BRS188: Dostarlimab-gxly
• The following NCCN Template has been DELETED:
  • BRS157: Atezolizumab + Albumin-bound PACLitaxel

NCCN has published updates to the NCCN Templates for Central Nervous System Cancers to reflect the currently published NCCN Guidelines for Central Nervous System Cancers v2.2021.

• The following NCCN Template has been DELETED:
  • CNS91: MBVP (Methotrexate/Carmustine/Teniposide/PredniSONE)

NCCN has published updates to the NCCN Templates for Kidney Cancer to reflect the currently published NCCN Guidelines for Kidney Cancer v2.2022.

• The following NEW NCCN Template has been published:
  • KDN37: Belzutifan
• Changes to the Indication section have been made to the following templates:
  • KDN17: Everolimus
  • KDN18: PAZOPanib
• References have been updated on the following templates:
  • KDN17: Everolimus
  • KDN18: PAZOPanib

NCCN has published updates to the following NCCN Guidelines with NCCN Evidence Blocks™:

• Colon Cancer, Version 3.2021
• Rectal Cancer, Version 2.2021
• Small Bowel Adenocarcinoma, Version 2.2021

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium^®), the NCCN Biomarkers Compendium^®, the NCCN Chemotherapy Order Templates (NCCN Templates^®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients^®, please visit NCCN.org/patientguidelines.

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.

About NCCN Flash Updates™

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium^®, and other NCCN Content.

Subscribe to NCCN Flash Updates™

Please note: 1. Third Party Content. The NCCN Content may contain content (such as figures, tables or illustrations) that NCCN licenses from third parties as displayed on NCCN Third Party Content FTP site: ftp://ftp1.nccn.org (To access: user name:content; password is NCCNcontent) (“Third Party Content”). Licensee shall be solely responsible for obtaining permissions from each such third party to use any such Third Party Content in the Permitted Works.

Access information on permissions and licensing of NCCN Content

Users may unsubscribe from Flash Updates at any time contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.